Baltimore’s Paragon is adding more space for biotech manufacturing in Maryland.
Through a partnership with Paragon Gene Therapy parent Catalent Biologics, the gene therapy-focused unit is assuming two clinical development and manufacturing sites currently operated by Gaithersburg-based vaccine developer Novavax and acquiring manufacturing equipment for $18 million in cash, the companies announced on Thursday.
Located in Gaithersburg and Rockville, the facilities offer Paragon more space for contract manufacturing and development operations, which have been expanding in the last year. More than 100 Novavax employees who work in manufacturing and quality will also join Paragon in the deal, but will continue to provide some services for Novavax. Paragon also expects to be able to manufacture commercial quantities of Novavax vaccines at the site.
READ FULL ARTICLE HERE
